Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Masonic Cancer Center, University of Minnesota
Age
0–21
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Any patient undergoing allogeneic hematopoietic stem cell transplantation (either 1st or subsequent)
Age ≤ 21 years
Adequate organ function within 14 days of enrollment, i.e. Creatinine: \< 1.5 x ULN and Hepatic: ALT, AST and total bilirubin \< 3 x ULN
Requires voriconazole to prevent or treat invasive fungal infection after undergoing stem cell transplantation
You may not be if
Has received voriconazole within 5 days prior to starting study therapy
History of hypersensitivity or severe intolerance to azoles
History, or current evidence, of cardiac arrhythmias defined as QTc ≥ 480 mm/sec
Receiving the following drugs and cannot be discontinued at least 24 hours before starting therapy: pimozide, quinidine, astemizole, ergot alkaloids.
Received one or more of the following drugs within 14 days prior to starting study, as they are potent inducers of hepatic microsomal enzymes: rifampin, rifabutin, carbamazepine, phenytoin, nevirapine, long-acting barbiturates.
Received sirolimus within the 14 days prior to starting study as voriconazole is a potent inhibitor of sirolimus metabolism
Receiving or anticipated need for methadone as co-administration with voriconazole potentially increases methadone exposure
Clareo Health | MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients
